Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

94.34 +1.75 (+1.89%)
Streaming Delayed Price Updated: 10:46 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of... 
Via StockStory
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook. 
Via Benzinga
Topics Intellectual Property
These S&P500 stocks have an unusual volume in today's session
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. 
Via Chartmill
Why Incyte (INCY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results. 
Via StockStory
Earnings Scheduled For October 28, 2025
 
Via Benzinga
Exploring Incyte's Earnings Expectations
 
Via Benzinga
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings. 
Via Benzinga
Topics Economy
Incyte (INCY) Q3 2025 Earnings Call Transcript
Incyte (INCY) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views
The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit. 
Via Investor's Business Daily
Topics Government
Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates
Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance. 
Via Chartmill
Topics Earnings
Incyte (NASDAQ:INCY) Reports Strong Q3
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share... 
Via StockStory
Topics Artificial Intelligence
What To Expect From Incyte’s (INCY) Q3 Earnings
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know. 
Via StockStory
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth. 
Via Benzinga
INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic... 
Via StockStory
Topics Artificial Intelligence
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
Via The Motley Fool
Topics Regulatory Compliance
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the... 
Via MarketMinute
Topics Economy Intellectual Property
What 14 Analyst Ratings Have To Say About Incyte
 
Via Benzinga
Which S&P500 stocks are gapping on Wednesday?
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index. 
Via Chartmill
2 Reasons to Like INCY and 1 to Stay Skeptical
Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly... 
Via StockStory
Topics Stocks
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs. 
Via Benzinga
Topics Stocks
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
 
Via Benzinga
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens and adults. 
Via Benzinga
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate
Incyte Corp (INCY) presents a strong value investing case with low P/E ratios, robust financial health, and high profitability in the biotech sector. 
Via Chartmill
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
3 Unpopular Stocks That Deserve a Second Chance
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.